Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$11.5MCash on Hand
CF+ Cash Runway
Follow BGM by emailGet an email when BGM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BGM, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Sep 24, 2026 ·
Shareholder vote BGM Group will consolidate its Class A, Class B and preferred shares at a 30-for-1 ratio, effective for trading on Nasdaq on October 1, 2026 under the new CUSIP G7307E131. Class A shares outstanding would fall from 380,623,358 to about 12,687,445. Form 6-K · SEC filing
Sep 8, 2026 ·
Shareholder vote Shareholders met at an extraordinary general meeting on September 5, 2026, with 273,457,527 of 400,623,358 ordinary shares present, constituting a quorum. All resolutions were passed; the full text is in the August 11, 2026 meeting notice. Form 6-K · SEC filing
Aug 28, 2026 ·
Earnings Reported unaudited first-half results for the six months ended March 31, 2026: net revenue of $24,295,443 versus $14,311,414 a year earlier, net loss attributable to BGM Group of $2,104,348, and cash and equivalents of $11,517,115. Form 6-K · SEC filing · Press release
Aug 11, 2026 ·
Shareholder vote Shareholders will vote at an extraordinary general meeting on September 5, 2026 on revoking prior share consolidation resolutions and approving a 30-for-1 share consolidation, a share capital increase from US$503,000 to US$15,090,000, and a fifth amended memorandum and articles. The board recommends voting FOR. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
BGM holds $11.5M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure:10 · Low
Cash runway not available
Shelf registration (F-3, Apr 2024) +10
Recent financing filings on SEC EDGAR:
Apr 10, 2024 · Shelf registration, up to $200M · F-3
Share count 35,750,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BGM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BGM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.